This week, Spyre is attending the Bank of America Securities 2024 Healthcare Conference in Las Vegas, NV. We are excited to host investor meetings at the conference and discuss our broad pipeline of potentially best-in-class antibodies. #antibody #TL1A #α4β7 #IBD
Spyre Therapeutics’ Post
More Relevant Posts
-
Hallo, #Medica2023! 🇩🇪 Catch our experts at Hall 3 / E71 in Düsseldorf, Germany from November 13th - 16th. Here's a little bit about us: 1) Our expertise is in creating high quality antigens and finding antibodies even against the most difficult targets. 🎯 2) We’ve produced everything from the simplest of human IgGs to afucosylated bispecific antibodies up to recombinant growth factors. 3) Our Phage Display and HybriFree platforms can rapidly identify and characterize high-quality antibodies. Meet you there! #icosagen #antibody #antibodydisocvery #proteinproduction #bioprocessing #celllinedevelopment #gmp #manufacturing
To view or add a comment, sign in
-
Save the date for our upcoming webinar with LCGC and BioPharm International and learn how AstraZeneca reduces charge heterogeneity analysis from weeks to minutes and fully characterizes ADCs using our Intabio ZT icIEF-UV/MS system! Register now 👇👇👇 #webinars #ADCs #biopharma
Learn how AstraZeneca reduces charge heterogeneity analysis from weeks to minutes and fully characterizes ADCs using SCIEX IntabioZT icIEF-UV/MS system. Identify and monitor charged modifications on ADC payloads and disentangle the contribution of the payload from the antibody modifications. Register here for August 29th, https://lnkd.in/eFjRwtTq #massspectrometry #massspec #biopharma #icIEFUVMS #proteins #antibodydrugconjugates #antibodydiscovery
To view or add a comment, sign in
-
-
In this week's #techNoteTuesday, we looked at ADCs. Join us next week to learn how AstraZeneca reduces charge heterogeneity analysis from weeks to minutes and fully characterizes ADCs using the SCIEX IntabioZT icIEF-UV/MS system. Register here for August 29th https://lnkd.in/eFjRwtTq. The SCIEX IntabioZT not only provides simultaneous imaged cIEF optical and MS data for rapid quantification and identification of charge variants, but it also uncovers variants not seen by other separation techniques, providing unprecedented characterization of protein-based biotherapeutics. Register here for August 29th, https://lnkd.in/eFjRwtTq #massspectrometry #massspec #biopharma #icIEFUVMS #proteins #antibodydrugconjugates #antibodydiscovery
Learn how AstraZeneca reduces charge heterogeneity analysis from weeks to minutes and fully characterizes ADCs using SCIEX IntabioZT icIEF-UV/MS system. Identify and monitor charged modifications on ADC payloads and disentangle the contribution of the payload from the antibody modifications. Register here for August 29th, https://lnkd.in/eFjRwtTq #massspectrometry #massspec #biopharma #icIEFUVMS #proteins #antibodydrugconjugates #antibodydiscovery
To view or add a comment, sign in
-
-
Learn how AstraZeneca reduces charge heterogeneity analysis from weeks to minutes and fully characterizes ADCs using SCIEX IntabioZT icIEF-UV/MS system. Identify and monitor charged modifications on ADC payloads and disentangle the contribution of the payload from the antibody modifications. Register here for August 29th, https://lnkd.in/eFjRwtTq #massspectrometry #massspec #biopharma #icIEFUVMS #proteins #antibodydrugconjugates #antibodydiscovery
To view or add a comment, sign in
-
-
Pfizer’s Sigvotatug vedotin showed durable ORR in addition to encouraging PFS and OS in patients with taxane-naive non-Sq NSCLC. This favorable and evolving phase I data has led to a global Phase III pivotal trial. Gain Exclusive Access to Expert Insights and Comprehensive Analysis with DelveInsight Business Research LLP at American Society of Clinical Oncology (ASCO) 2024! https://lnkd.in/gY5dn67p #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders
To view or add a comment, sign in
-
🔬 Are you attending #CHIPepTalk this week?! Discover cutting-edge insights at Poster A31 on "High Throughput Platforms to Evaluate the Stability of a Bispecific Antibody through Forced Degradation." 🚀 Uncover the power of the #LabChip in assessing the stability of your bispecific antibodies. 💡 #BispecificAntibodies #LabChip #ResearchInnovation #ScienceConference #Innovation #ScientificResearch #AntibodyResearch #LifeSciences #Biotech
Attending #CHIPepTalk? Don’t miss poster A31, High Throughput Platforms to Evaluate the Stability of a Bispecific Antibody Using Forced Degradation, to learn how to assess the stability of your bispecific antibodies. #BispecificAntibodies #LabChip
To view or add a comment, sign in
-
-
😍 Check out the next #MPN roundtable segment with Ruben Mesa, MD; Naveen Pemmaraju, MD; Sanam Loghavi, MD; and Olatoyosi Odenike, MD! The panel discusses the four JAK inhibitors approved by the FDA for #myelofibrosis: ruxolitinib, fedratinib, pacritinib, and momelotinib. ➡️ https://buff.ly/3KDEG04
Which JAK inhibitors Are Clinicians Prescribing for Myelofibrosis? | Blood Cancers Today
bloodcancerstoday.com
To view or add a comment, sign in
-
These are just a few of the reasons leading healthcare providers choose RLS. Experience the RLS difference today! https://rls.bio/ #nuclearmedicine #radiopharmaceuticals
To view or add a comment, sign in
-
-
In the world of #autoimmune testing, RNP antibody results may not always be what they seem. Hear Dr. Lisa Peterson of ARUP Laboratories review RNP antigen structure, RNP antibody detection methods, and case study examples. Register for the May 7th #webinar. https://bit.ly/3U1keM1 #AutoimmuneDisease
To view or add a comment, sign in
-
-
Dive into R/R DLBCL treatment with bispecific antibodies 🧬. Join experts to gain skills in selecting therapies, managing AEs, & using the latest data for optimal safety. Enhance your confidence & treatment strategies 💉🔬 http://ms.spr.ly/6041Ykqut #ASCO24
To view or add a comment, sign in
-